Topoisomerase II Alpha As a Universal Tumor Antigen: Antitumor Immunity in Murine Tumor Models and H-2K(b)-restricted T Cell Epitope

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2009 Nov 26

PMID 19936747

Citations 4

Authors

Jung-Sun Park

Hye-Sung Kim

Mi-Young Park

Chang-Hyun Kim

Yeun-Jun Chung

Yong-Kil Hong

Tai-Gyu Kim

Affiliations

Soon will be listed here.

Abstract

Topoisomerase II alpha (Top2alpha) is an attractive candidate to be used as a tumor antigen for cancer immunotherapy, because it is abundantly expressed in various tumors and serves as a target for a number of chemotherapeutic agents. In this study, we demonstrated the immunogenicity of Top2alpha, using dendritic cells (DC) electroporated with RNA encoding the Top2alpha C-terminus (Top2alphaCRNA/DC). Top2alphaCRNA/DC were able to demonstrate in vitro stimulation of T cells from mice that were previously vaccinated with Top2alpha-expressing tumor lysate-pulsed DC. Vaccination with Top2alphaCRNA/DC induced Top2alpha-specific T cell responses in vivo as well as antitumor effects in various murine tumor models including MC-38, B16F10, and GL26. DC pulsed with p1327 (DSDEDFSGL), defined as an epitope presented by H-2K(b), also induced Top2alpha-specific immune responses and antitumor effects. Based on these data, Top2alpha is suggested to be a universal target for cancer immunotherapy.

Citing Articles

Late-stage MC38 tumours recapitulate features of human colorectal cancer - implications for appropriate timepoint selection in preclinical studies.

Shields N, Peyroux E, Ferguson A, Steain M, Neumann S, Young S Front Immunol. 2023; 14:1152035.

PMID: 37153625 PMC: 10160415. DOI: 10.3389/fimmu.2023.1152035.

Target Selection for T-Cell Therapy in Epithelial Ovarian Cancer: Systematic Prioritization of Self-Antigens.

Schossig P, Coskun E, Arsenic R, Horst D, Sehouli J, Bergmann E Int J Mol Sci. 2023; 24(3).

PMID: 36768616 PMC: 9916968. DOI: 10.3390/ijms24032292.

Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer.

Donaldson B, Al-Barwani F, Pelham S, Young K, Ward V, Young S J Immunother Cancer. 2017; 5(1):69.

PMID: 28806910 PMC: 5556368. DOI: 10.1186/s40425-017-0270-1.

STAT3 silencing enhances the efficacy of the HSV.tk suicide gene in gastrointestinal cancer therapy.

Ahn Y, Yi H, Shin J, Lee K, Shin S, Lee S Clin Exp Metastasis. 2012; 29(4):359-69.

PMID: 22350508 DOI: 10.1007/s10585-012-9458-4.

References

Muller M, Grunebach F, Nencioni A, Brossart P . Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes. J Immunol. 2003; 170(12):5892-6. DOI: 10.4049/jimmunol.170.12.5892. View

Wong N, Yeo W, Wong W, Wong N, Chan K, Mo F . TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer. 2008; 124(3):644-52. DOI: 10.1002/ijc.23968. View

Nair S, Boczkowski D, Morse M, Cumming R, Lyerly H, Gilboa E . Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol. 1998; 16(4):364-9. DOI: 10.1038/nbt0498-364. View

Van Tendeloo V, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C . Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood. 2001; 98(1):49-56. DOI: 10.1182/blood.v98.1.49. View

Willman J, Holden J . Immunohistochemical staining for DNA topoisomerase II-alpha in benign, premalignant, and malignant lesions of the prostate. Prostate. 2000; 42(4):280-6. DOI: 10.1002/(sici)1097-0045(20000301)42:4<280::aid-pros5>3.0.co;2-p. View

Zhao H, Yu H, Liu Y, Wang Y, Cai W . DNA topoisomerase II-alpha as a proliferation marker in human gliomas: correlation with PCNA expression and patient survival. Clin Neuropathol. 2008; 27(2):83-90. DOI: 10.5414/npp27083. View

Nair S, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski J . Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med. 2000; 6(9):1011-7. DOI: 10.1038/79519. View

Schrader C, Meusers P, Brittinger G, Teymoortash A, Siebmann J, Janssen D . Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia. 2004; 18(7):1200-6. DOI: 10.1038/sj.leu.2403387. View

Woessner R, Mattern M, Mirabelli C, Johnson R, Drake F . Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 1991; 2(4):209-14. View

10.

Gordan J, Vonderheide R . Universal tumor antigens as targets for immunotherapy. Cytotherapy. 2002; 4(4):317-27. DOI: 10.1080/146532402760271091. View

11.

Awwad M, NORTH R . Radiosensitive barrier to T-cell-mediated adoptive immunotherapy of established tumors. Cancer Res. 1990; 50(8):2228-33. View

12.

Mano M, Awada A, Di Leo A, Durbecq V, Paesmans M, Cardoso F . Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma. Gynecol Oncol. 2004; 92(3):887-95. DOI: 10.1016/j.ygyno.2003.12.010. View

13.

Scanlan M, Simpson A, Old L . The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 2004; 4:1. View

14.

Vonderheide R . Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene. 2002; 21(4):674-9. DOI: 10.1038/sj.onc.1205074. View

15.

Capranico G, Tinelli S, Austin C, Fisher M, Zunino F . Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim Biophys Acta. 1992; 1132(1):43-8. DOI: 10.1016/0167-4781(92)90050-a. View

16.

Kanta S, Yamane T, Dobashi Y, Mitsui F, Kono K, Ooi A . Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Hum Pathol. 2006; 37(10):1333-43. DOI: 10.1016/j.humpath.2006.05.008. View

17.

Kosari F, Munz J, Dilara Savci-Heijink C, Spiro C, Klee E, Kube D . Identification of prognostic biomarkers for prostate cancer. Clin Cancer Res. 2008; 14(6):1734-43. DOI: 10.1158/1078-0432.CCR-07-1494. View

18.

Boczkowski D, Nair S, Snyder D, Gilboa E . Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med. 1996; 184(2):465-72. PMC: 2192710. DOI: 10.1084/jem.184.2.465. View

19.

Hande K . Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Acta. 1998; 1400(1-3):173-84. DOI: 10.1016/s0167-4781(98)00134-1. View

20.

Rakhmilevich A, NORTH R . Elimination of CD4+ T cells in mice bearing an advanced sarcoma augments the antitumor action of interleukin-2. Cancer Immunol Immunother. 1994; 38(2):107-12. PMC: 11038153. DOI: 10.1007/BF01526205. View